**Table e-1.** Clinical phenotypes, cancer associations and final diagnosis of 90 non-confirmed EUROLINE PNS 12 Ag (Euroimmun).

|  |  |  |  |
| --- | --- | --- | --- |
| Non-confirmed staining (n) | Clinical presentation (n, %) | Cancer\* (n) | Final diagnosis (n) |
| Yo (41) | Cerebellar syndrome (5; 12.2%) | No | Creutzfeldt-Jakob disease (1)  Post-infectious cerebellitis (1)  Cerebellar multisystem atrophy (1)  Alcoholic cerebellar degeneration (1)  Barbiturates overdose (1) |
| Various phenotypes (36; 87.8%) | Lung adenocarcinoma (1) | Stroke |
| No (35) | Polyneuropathies (7)  Other neuromuscular disorders (3)  Stroke (2)  Epilepsy (3)  Infectious meningoencephalitis (3)  Degenerative dementia/parkinsonism (3)  ALS (3)  Metabolic-toxic CNS disorders (3)  Brain primary tumors (2)  MS (1)  Acute transverse myelitis (1)  Bickerstaff´s encephalitis (1)  Anti-NMDAR encephalitis (1)  Transient diplopia after ocular surgery (1)  Drug reaction with eosinophilia and systemic symptoms (1) |
| Ma2 (17) | Encephalitis with brainstem, diencephalic and limbic involvement (0) |  |  |
| Various phenotypes (17, 100%) | Lung adenocarcinoma (1) | Meningeal carcinomatosis |
| SCLC (1) | Attention deficit |
| No (15) | Polyneuropathies (4)  Degenerative dementia/parkinsonism (2)  Psychiatric disorders (2)  Anti-LGI1 encephalitis (1)  Vogt-Koyanagi-Harada disease (1)  ALS (1)  Metabolic-toxic CNS disorders (1)  Idiopathic late-onset cerebellar ataxia (1)  Hypertrophic pachymeningitis due to intracranial hypotension (1)  Gait imbalance (1) |
| Amphiphysin (10) | Stiff-person syndrome (0) |  |  |
| Cerebellar syndrome (2; 20%) | No | Cerebellar multisystem atrophy (1)  Barbiturates overuse (1) |
| Neuropathy (4; 40%) | No | Metabolic-toxic polyneuropathies (2)  CIDP (2) |
| Various phenotypes (4; 40%) | No | MS (1)  CNS vasculitis (1)  Amyloid angiopathy (1)  Psychotic depression (1) |
| CV2/CRMP5 (10) | Encephalomyelitis, sensory neuronopathy (0) |  |  |
| Limbic encephalitis (1; 10%) | No | Anti-LGI1 encephalitis (1) |
| Various phenotypes (9; 90%) | Uterine cancer (1) | ALS |
| Malignant thymoma (1) | Morvan’s syndrome (anti-CASPR2) |
| No (5) | ALS (2)  Anti-NMDAR encephalitis (1)  Stroke (1)  MS (1)  Degenerative dementia/parkinsonism (1)  Diabetic polyneuropathy (1) |
| Hu (6) | Encephalomyelitis, sensory neuronopathy (0) |  |  |
| Limbic encephalitis (1; 17%) | No | Anti-LGI1 encephalitis |
| Cerebellar syndrome (1; 17%) | No | Anti-GAD cerebellar ataxia |
| Various phenotypes (4; 66%) | SCLC (1) | Leukoencephalopathy after radiotherapy |
| No (3) | Stroke (1)  ALS (1)  MS (1) |
| Tr/DNER (4) | Cerebellar syndrome (0) |  |  |
| Various phenotypes (4; 100%) | No | Polyneuropathy (1)  Metabolic-toxic CNS disorders (1)  Transient diplopia after ocular surgery (1)  Drug reaction with eosinophilia and systemic symptoms (1) |
| Ri (2) | Opsoclonus-myoclonus, brainstem encephalitis, cerebellar syndrome (0) |  |  |
| Various phenotypes (2; 100%) | No | CIDP (2) |

\*Primary brain tumors are not included within this category.

*Abbreviations: ALS, amyotrophic lateral sclerosis, CIDP, chronic inflammatory demyelinating polyneuropathy, CASPR2,* anti-contactin-associated protein-like 2; *CNS, central nervous system; CRMP5, collapsin response-mediator protein-5; DNER, delta/notch-like epidermal growth factor-related receptor; LGI1, leucin-rich glioma-inactivated protein 1; MS, multiple sclerosis; NMDAR, N-methyl-D-aspartate receptor; SCLC, small-cell lung cancer.*